Partners Capital Investment Group, LLP Incyte Corp Transaction History

Partners Capital Investment Group, LLP

$5.57 Billion
Q1 2025

A detailed history of Partners Capital Investment Group, LLP transactions in Incyte Corp stock. As of the latest transaction made, Partners Capital Investment Group, LLP holds 32,216 shares of INCY stock, worth $2.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

32,216

Holding current value

$2.2 Million

% of portfolio

0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$60.0 - $75.26 $1.93 Million - $2.42 Million	32,216 New	32,216 $1.95 Million
Q3 2024 Nov 05, 2024	SELL	$57.33 - $68.61 $240,614 - $287,956	-4,197 Reduced 10.81%	34,632 $2.29 Million
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $1.99 Million - $2.48 Million	38,829 New	38,829 $2.35 Million
Q4 2023 Feb 12, 2024	BUY	$52.16 - $64.19 $850,729 - $1.05 Million	16,310 Added 50.05%	48,896 $3.07 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $138,359 - $157,902	-2,395 Reduced 6.85%	32,586 $1.88 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $286,343 - $354,745	-4,698 Reduced 11.84%	34,981 $2.18 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $3.13 Million - $3.83 Million	-44,542 Reduced 52.89%	39,679 $2.87 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $4.52 Million - $5.65 Million	-67,225 Reduced 44.39%	84,221 $6.76 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $4.5 Million - $5.63 Million	-67,969 Reduced 30.98%	151,446 $10.1 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $5.93 Million - $7.46 Million	-89,642 Reduced 29.01%	219,415 $16.7 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $874,368 - $1.06 Million	13,244 Added 4.48%	309,057 $24.5 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $617,184 - $722,127	9,744 Added 3.41%	295,813 $21.7 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $1.28 Million - $1.57 Million	18,686 Added 6.99%	286,069 $19.7 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1.58 Million - $1.74 Million	19,838 Added 8.01%	267,383 $22.5 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $191,418 - $253,059	2,518 Added 1.03%	247,545 $20.1 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $3.48 Million - $4.21 Million	43,080 Added 21.33%	245,027 $21.3 Million
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $2.23 Million - $2.87 Million	26,177 Added 14.89%	201,947 $18.1 Million
Q2 2020 Aug 12, 2020	BUY	$74.18 - $108.93 $3.04 Million - $4.46 Million	40,970 Added 30.39%	175,770 $18.3 Million
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $204,324 - $278,026	-3,234 Reduced 2.34%	134,800 $9.87 Million
Q4 2019 Feb 13, 2020	BUY	$73.04 - $95.72 $249,650 - $327,170	3,418 Added 2.54%	138,034 $12.1 Million
Q3 2019 Nov 13, 2019	BUY	$72.82 - $86.52 $2.69 Million - $3.19 Million	36,898 Added 37.76%	134,616 $9.99 Million
Q2 2019 Aug 12, 2019	BUY	$73.52 - $88.7 $603,011 - $727,517	8,202 Added 9.16%	97,718 $8.3 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $628,799 - $872,265	9,893 Added 12.42%	89,516 $7.7 Million
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $2.96 Million - $3.54 Million	50,563 Added 174.0%	79,623 $5.06 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $231,439 - $278,214	3,748 Added 14.81%	29,060 $2.01 Million
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $319,158 - $440,475	5,245 Added 26.14%	25,312 $1.7 Million
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $911,583 - $1.11 Million	10,975 Added 120.71%	20,067 $1.67 Million
Q4 2017 Feb 13, 2018	BUY	$93.56 - $116.6 $850,647 - $1.06 Million	9,092	9,092 $861,000

Others Institutions Holding INCY

# of Institutions

695

Shares Held

194M

Call Options Held

564K

Put Options Held

331K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Partners Capital Investment Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Partners Capital Investment Group, LLP with notifications on news.

Account

Partners Capital Investment Group, LLP Incyte Corp Transaction History